Reviews/Perioperative Immunotherapy Solid Tumours/Pathological complete response as surrogate for non-small cell lung cancer immune checkpoint inhibitor therapy
Nsclc · PERIO-NSCLC-04 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
When patients with resectable lung cancer have no viable tumour left after pre-surgery immunotherapy combined with chemotherapy, they tend to go longer without their cancer returning and to live longer overall. The clearest patient-level evidence comes from one large trial, which linked a complete pathological response to a much lower risk of cancer events [3] and to markedly higher five-year survival [12]. Several independent trials run by different sponsors all pushed both complete-response rates and survival in the same direction [11],[13],[14],[15], and a separate trial reached the same conclusion about survival [10]. Chemotherapy-era studies from before immunotherapy had already shown that a complete response marks a better outlook [21],[25]. The panel placed the claim high because the direction is unanimous across the included primary trials, but held it off the ceiling because the survival link rests on a small subgroup within a single trial and on analyses that were exploratory rather than designed to prove cause and effect.
At the patient level, CheckMate 816 associated 0% residual viable tumour with event-free survival at a hazard ratio of 0.18 [3], and its overall-survival analysis reported five-year survival of 95.3% with a pathological complete response versus 55.7% without [12]. NADIM II independently reported that pathological complete response correlates with excellent survival [10]. Four independent phase 3 trials of immunotherapy plus chemotherapy concordantly raised both complete-response rate and survival [11],[13],[14],[15]. Pre-immunotherapy cohorts establish the complete response as prognostic in the chemotherapy era [21],[25], and a related analysis ties pathological response to prolonged disease-free survival [30]. No included paper contradicts the direction of the association. The contested point: The division is over the overall-survival limb: it rests essentially on one trial's exploratory subgroup, with a wide confidence interval (82.7 to 98.8) and small pathological-complete-response numbers [12], and is far less mature than the event-free survival evidence [3]. The deeper unresolved question is whether the complete response drives survival or merely marks intrinsically favourable tumour biology, which the surrogacy meta-analyses excluded by the study-type filter would have addressed.
All 30 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Perioperative Immunotherapy Solid Tumours, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The patient-level pCR-to-OS association is carried essentially by one trial's exploratory subgroup ([12]), with a wide confidence interval (82.7 to 98.8) and small pCR numbers; the OS limb is far less mature than the EFS limb.
These are exploratory/post-hoc associations, not prespecified causal surrogacy; pCR patients plausibly carry intrinsically favourable biology, so the association may be prognostic rather than demonstrating pCR itself drives survival. The meta-analytic surrogacy evidence that would adjudicate this was excluded by the study-type filter.
Where it remains uncertain. The overall-survival association is carried by a single trial's small exploratory subgroup with a wide confidence interval [12], and these are prognostic associations rather than prespecified causal surrogacy.
Aleatory
A complete response is uncommon (17-24% in [11],[13],[15]), so survival estimates in the complete-response arm rest on modest numbers and a wide OS confidence interval of 82.7 to 98.8 [12].
Epistemic
The patient-level complete-response-to-OS link rests on fewer mature exploratory analyses than the event-free survival link, chiefly the single subgroup in [12].
Inferential
Complete-response patients may carry intrinsically favourable tumour biology, so the association may be prognostic rather than demonstrating that the complete response itself drives survival.
The load-bearing papers from a corpus of 30, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Direct patient-level association between pathologic complete response (0% RVT) and event-free survival under nivolumab plus chemotherapy.
“Regardless of LN involvement, EFS improved with 0% versus >0% RVT-PT (hazard ratio = 0.18).”
Panel auditInternal validity: high · scope of inference: Residual-viable-tumor burden as a survival surrogate for neoadjuvant nivolumab plus chemotherapy in resectable lung cancer (EFS, not OS).Key limitations: EFS only, no OS · exploratory analysis · HR without CI/p in abstract
Independent confirmation (NADIM II) that pCR correlates with excellent survival after perioperative chemoimmunotherapy.
“Although pathologic complete response (pCR) correlates with excellent survival outcomes, some patients without pCR still exhibit long-term survival.”
Panel auditInternal validity: medium · scope of inference: Prognostic refinement of pCR by MRD after perioperative chemoimmunotherapy in resectable NSCLC.Key limitations: small MRD subset · pCR-survival stated qualitatively · secondary analysis
Phase 3 trial establishing concurrent EFS and pCR benefit of ICI+chemo.
“neoadjuvant nivolumab plus chemotherapy resulted in significantly longer event-free survival and a higher percentage of patients with a pathological complete response than chemotherapy alone”
Panel auditInternal validity: high · scope of inference: Treatment effect of neoadjuvant nivolumab plus chemotherapy on EFS and pCR in resectable NSCLC.Key limitations: treatment effect not pCR-survival link · no pCR-stratified survival in abstract
The abstract links MPR to DFS, but the claim's specific contrast — pCR after ICI plus chemotherapy — is not reported (this is monotherapy and MPR).
Panel auditInternal validity: low · scope of inference: Feasibility and MPR-DFS association of neoadjuvant durvalumab monotherapy in early-stage resectable NSCLC.Key limitations: monotherapy not ICI+chemo · MPR not pCR · single-arm, early termination
4 of 30 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Concordant primary-trial evidence directly supports the association for both endpoints, held just below the ceiling because the overall-survival link and causal surrogacy remain exploratory.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Mature multi-trial patient-level pCR-to-OS analysis. The overall-survival limb rests on one exploratory subgroup [12], so the durability and generalisability of the survival association are uncertain. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: Pooled individual-patient-data analysis of complete response versus overall survival across the phase 3 immunotherapy-plus-chemotherapy trials with long follow-up.
Open question: Does the pathological-complete-response-to-overall-survival association hold across multiple immunotherapy-plus-chemotherapy trials at the patient level with mature follow-up? Why it is still open: Only one trial's exploratory subgroup, with a wide confidence interval, carries the overall-survival link in this corpus [12].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19